HROW: Harrow, Inc.
About
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Current Value
$40.031 Year Return
Current Value
$40.031 Year Return
Key Details
Market Cap
$1.41B
P/E Ratio
-42.18
1Y Stock Return
330.59%
1Y Revenue Growth
48.15%
Dividend Yield
0.00%
Price to Book
24.5
Strategies that include HROW
Stock's related to HROW
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CLNE | 49.65% | $589.93M | -23.92% | 0.00% |
| XPEL | 48.37% | $1.18B | -7.73% | 0.00% |
| HCAT | 46.62% | $458.79M | 0.00% | 0.00% |
| ICUI | 46.09% | $4.15B | +104.38% | 0.00% |
| APPS | 44.20% | $125.51M | -75.85% | 0.00% |
| DGII | 43.87% | $1.14B | +27.53% | 0.00% |
| YETI | 43.22% | $3.22B | -10.71% | 0.00% |
| ALDX | 43.20% | $294.18M | +102.46% | 0.00% |
| XMTR | 42.25% | $1.48B | +50.13% | 0.00% |
| ACVA | 42.06% | $3.60B | +39.71% | 0.00% |
| KVYO | 41.61% | $9.29B | +24.95% | 0.00% |
| CLPT | 40.70% | $302.60M | +84.68% | 0.00% |
| HIPO | 38.96% | $708.87M | +243.57% | 0.00% |
| FOLD | 38.84% | $2.84B | -11.52% | 0.00% |
| CPRX | 38.35% | $2.55B | +55.68% | 0.00% |
| AGYS | 37.95% | $3.44B | +39.55% | 0.00% |
| AXGN | 37.00% | $561.11M | +113.93% | 0.00% |
| ONON | 36.16% | $17.09B | +91.60% | 0.00% |
| AMRX | 36.07% | $2.62B | +88.81% | 0.00% |
| SN | 35.91% | $13.84B | +118.64% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TPST | 0.01% | $37.75M | -77.59% | 0.00% |
| CHCT | 0.03% | $527.85M | -29.47% | 9.98% |
| HIW | 0.04% | $3.34B | +74.29% | 6.42% |
| NGL | 0.05% | $572.94M | +5.60% | 0.00% |
| UFCS | -0.05% | $696.15M | +35.19% | 2.34% |
| LMT | 0.08% | $126.40B | +18.99% | 2.36% |
| RKT | -0.09% | $2.00B | +53.18% | 0.00% |
| CHRW | 0.10% | $12.89B | +32.52% | 2.24% |
| SMPL | 0.10% | $3.81B | -3.16% | 0.00% |
| HAYN | 0.10% | $779.50M | +25.76% | 1.44% |
| NOAH | -0.10% | $775.22M | -3.69% | 8.96% |
| NOC | 0.13% | $71.54B | +4.23% | 1.60% |
| HFWA | 0.13% | $873.99M | +47.58% | 3.58% |
| CUZ | -0.13% | $4.89B | +57.48% | 4.17% |
| GCMG | 0.15% | $541.48M | +44.26% | 3.64% |
| UE | -0.15% | $2.93B | +40.88% | 2.86% |
| KRNY | -0.16% | $526.32M | +4.49% | 5.40% |
| ICL | 0.18% | $5.65B | -14.79% | 4.46% |
| WMS | 0.18% | $10.01B | +9.46% | 0.46% |
| FATE | 0.20% | $248.29M | -11.02% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FROG | -30.44% | $3.34B | +11.67% | 0.00% |
| MCK | -25.36% | $78.15B | +35.51% | 0.42% |
| IRWD | -19.10% | $609.71M | -59.34% | 0.00% |
| RAMP | -18.49% | $1.86B | -16.17% | 0.00% |
| BMBL | -17.63% | $845.98M | -43.90% | 0.00% |
| ACIC | -17.49% | $631.49M | +58.21% | 0.00% |
| MNST | -16.76% | $52.25B | -1.95% | 0.00% |
| GDRX | -15.68% | $1.62B | -24.15% | 0.00% |
| CCEC | -14.50% | $1.02B | +28.03% | 3.26% |
| ED | -13.73% | $33.59B | +7.16% | 3.43% |
| DUK | -13.69% | $87.74B | +26.37% | 3.65% |
| BROS | -13.57% | $5.67B | +74.77% | 0.00% |
| TCTM | -12.96% | $8.10M | -42.99% | 0.00% |
| CDLX | -12.13% | $178.39M | -54.00% | 0.00% |
| AGO | -11.41% | $4.66B | +37.77% | 1.01% |
| ES | -11.09% | $22.60B | +4.85% | 4.58% |
| QTTB | -10.83% | $354.34M | +188.64% | 0.00% |
| CTLT | -10.54% | $10.69B | +47.79% | 0.00% |
| GFL | -10.36% | $17.93B | +54.54% | 0.12% |
| D | -10.34% | $48.38B | +24.06% | 4.62% |
ETF's related to HROW
News
Yahoo
NASHVILLE, Tenn., November 20, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration ("FDA") ea
Finnhub
NASHVILLE - Harrow , a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual...
SeekingAlpha
Read an analysis on Harrow's Q3 earnings, inventory issues and strategic pivots, with a focus on VEVYE and IHEEZO's potential for recovery in Q4.
Yahoo
Harrow Inc (HROW) reports a 44% revenue increase, strategic pivots, and addresses inventory challenges in its Q3 2024 earnings call.
SeekingAlpha
Harrow, Inc. (NASDAQ:HROW) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ETCompany ParticipantsJamie Webb - Director, Communications &...
SeekingAlpha
Harrow, Inc. 2024 Q3 - Results - Earnings Call Presentation
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.